Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Prognostic value of interleukin-10 and tumor necrosis factor-α polymorphisms in patients with hepatocellular carcinoma treated with transarterial chemoembolization

The Egyptian Journal of Internal Medicine volume 31, pages 254–260 (2019)Cite this article

En

Abstract

Background

Transarterial chemoembolization (TACE), a locoregional therapy, is widely recommended as first-line treatment for intermediate-stage hepatocellular carcinoma (HCC). Several prognostic indices have been used to predict overall survival in HCC patients undergoing the procedure.

Patients and methods

A total of 73 patients with HCC, candidate for TACE attending to HCC clinic, Specialized Medical Hospital, Mansoura University, were subjected to full history taking, physical examination, laboratory profile and testing for interleukin (IL)-10 and tumor necrosis factor (TNF)-α polymorphisms. Aggressiveness index is calculated for all patients and followed-up for 4 weeks after TACE to asses response. According to IL-10 and TNF-α polymorphisms results, patients were divided into groups and compared.

Results

The aggressiveness index is significantly higher in the TT/AT haplotype of IL-10 and GG haplotype of TNF-α in comparison with the other haplotypes. The TT/AT haplotype of IL-10 and GG haplotype of TNF-α are significantly associated with less favorable outcome after TACE, wherein 64.3 and 56.25% of patients showed residual active tumor tissue, respectively.

Conclusion

The TT/AT haplotype of IL-10 and GG haplotype of TNF-α are associated with more aggressive pattern of HCC and less favorable outcome after TACE; hence, these patients must be treated as early as possible.

References

  1. Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015; 7: 566–574.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Llovet JM, Br C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329–338.

    Article  CAS  PubMed  Google Scholar 

  3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.

    Article  PubMed  Google Scholar 

  4. Geschwind JF, Gholam PM, Goldenberg A, Mantry P, Martin RC, Piperdi B et al. Use of transarterial chemoembolization (TACE) and sorafenib in patients with unresectable hepatocellular carcinoma: US regional analysis of the GIDEON registry. Liver Cancer 2016; 5: 37–46.

    Article  CAS  PubMed  Google Scholar 

  5. Kadalayil L, Benini R, Pallan L, O’Beirne J, Marelli L, Yu D et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013; 24: 2565–2570.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Carr BI, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology 2016; 90: 215–220.

    Article  CAS  PubMed  Google Scholar 

  7. Aroucha DC, Carmo RF, Vasconcelos LR, Lima RE, Mendonca TF, Arnez LE et al. TNF-α and IL-10 polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals. J Med Virol 2016; 88: 1587–1595.

    Article  CAS  PubMed  Google Scholar 

  8. Ventura N, Carr BI, Kori I, Guerra V, Shibolet O. Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization. World J Gastroenterol 2018; 24: 1641–1649.

    Article  PubMed  PubMed Central  Google Scholar 

  9. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908–943.

    Article  Google Scholar 

  10. Shire NJ, Sherman KE. Epidemiology of hepatitis C virus: a battle on new frontiers. Gastroenterol Clin North Am 2015; 44: 699.

    Article  PubMed  Google Scholar 

  11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. Version 3. 2017.

  12. Heimbach JK, Kulik LM, Finn R, Sirlin CB, Abecassis MM, Roberts LR et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2017; 67: 358–380.

    Article  Google Scholar 

  13. Kudo M. Regorafenib as second-line systemic therapy may change the treatment strategy and management paradigm for hepatocellular carcinoma. Liver Cancer 2016; 5: 235–244.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58–S68.

    Article  PubMed  Google Scholar 

  15. Seyda Seydel G, Kucukoglu O, Altinbasv A, Demir OO, Yilmaz S, Akkiz H et al. Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries. Ann Hepatol 2016; 15:662–672.

    CAS  PubMed  Google Scholar 

  16. Swiatek BJ. Is interleukin-10 gene polymorphism a predictive marker in HCV infection? Cytokine Growth Factor Rev 2012; 23: 47–59.

    Article  CAS  PubMed  Google Scholar 

  17. Talaat RM, Esmail AA, Elwakil R, Gurgis AA, Nasr MI. Tumor necrosis factor-alpha _308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients. Chin J Cancer 2012; 31: 29–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Radwan MI, Pasha HF, Mohamed RH, Hussien HI, El-Khshab MN. Influence of transforming growth factor-b1 and tumor necrosis factor-? genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine 2012; 60: 271–276.

    Article  CAS  PubMed  Google Scholar 

  19. Baghel K, Srivastava RN, Chandra A, Goel SK, Agrawal J, Kazmi HR, Raj S. TNF-a, IL-6, and IL-8 cytokines and their association with TNF-? −308 G/A polymorphism and postoperative sepsis. J Gastrointest Surg 2014; 18: 1486–1494.

    Article  PubMed  Google Scholar 

  20. Karimi M, Goldie LC, Cruickshank MN, Moses EK, Abraham LJ. A critical assessment of the factors affecting reporter gene assays for promoter SNP function: a reassessment of −308 TNF polymorphism function using a novel integrated reporter system. Eur J Hum Genet 2009; 17: 1454–1462.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Vikram NK, Bhatt SP, Bhushan B, Luthra K, Misra A, Poddar PK et al. Associations of −308G/A polymorphism of tumor necrosis factor (TNF)-? gene and serum TNF-? levels with measures of obesity, intra-abdominal and subcutaneous abdominal fat, subclinical inflammation and insulin resistance in Asian Indians in north India. Dis Markers 2011; 31: 39–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Loosen SH, Schulze-Hagen M, Leyh C, Benz F, Vacur M, Kuhl C et al. IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies. Int J Mol Sci 2018; 19: 1766.

    Article  PubMed Central  Google Scholar 

  23. Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics 2017; 7: 1543–1588.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol 2016; 64: 1403–1415.

    Article  CAS  PubMed  Google Scholar 

  25. Bouzgarrou N, Hassen E, Farhat K, Bahri O, Gabbouj S, Maamouri N et al. Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 2009; 70: 230–236.

    Article  CAS  PubMed  Google Scholar 

  26. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and antiinflammatory effect. Hepatology 2003; 38: 859–868.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hepatology and Gastroentrology Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt

    Ahmed A. Ghafar MD, Elsayed Ghoneem & Salah Rozaik

  2. Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt

    Ahmed Akef & Metwaly Mortada

Authors
  1. Ahmed A. Ghafar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elsayed Ghoneem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salah Rozaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed Akef
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Metwaly Mortada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed A. Ghafar MD.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghafar, A.A., Ghoneem, E., Rozaik, S. et al. Prognostic value of interleukin-10 and tumor necrosis factor-α polymorphisms in patients with hepatocellular carcinoma treated with transarterial chemoembolization. Egypt J Intern Med 31, 254–260 (2019). https://doi.org/10.4103/ejim.ejim_110_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_110_18

Keywords